OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. DeCesaris on Classical vs Contemporary Indications for Radiation in Breast Cancer

April 26th 2022

Cristina DeCesaris, MD, discusses classical indications for breast cancer radiation and how these methods are being contextualized in the contemporary treatment era.

Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHL

April 26th 2022

Evandro D. Bezerra, MD, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma who have progressed on anti-CD19 CAR T-cell therapy.

Dr. Blay on the Exploration of BI 907828 in Patients With Sarcoma

April 25th 2022

Jean-Yves Blay, MD, discusses the exploration of BI 907828 in patients with sarcoma.

Dr. Verstovsek on the Mechanism of Action of Momelotinib in Myelofibrosis

April 25th 2022

Srdan Verstovsek, MD, PhD, discusses the mechanisms of action of momelotinib in myelofibrosis.

Dr. Akbar on the Efficacy of Monoclonal Antibodies Across Various Trials in R/R ALL

April 25th 2022

Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Dr. Abid on Adaptive Lymphodepletion in CAR T-Cell Recipients in R/R B-Cell NHL

April 25th 2022

Muhammad Bilal Abid, MD, MRCP, discusses the impact of adaptive lymphodepletion in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma who received CAR T-cell therapy.

Dr. Dahiya on Long-Term, Real-World Follow-Up of Axi-Cel in LBCL

April 25th 2022

Saurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.

Dr. Shadman on the Efficacy of MB-106 in Relapsed/Refractory NHL and CLL

April 25th 2022

Mazyar Shadman, MD, MPH, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Riedell on the Examination of Axi-Cel Therapy in High-Risk LBCL

April 25th 2022

Peter Riedell, MD, discusses the use of axicabtagene ciloleucel in high-risk large B-cell lymphoma, as evaluated on the phase 2 ZUMA-12 trial.

Dr. Khushalani on the Mechanism of Action of RP1 in Cancer Care

April 22nd 2022

Nikhil Khushalani, MD, discusses the mechanism of action vusolimogene oderparepvec in cancer care.

Dr. Lin on Treatment Updates in CAR T-Cell Therapy in Myeloma

April 21st 2022

Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

Dr. Edington on the Utilization of TIL Therapy in Melanoma

April 21st 2022

Howard D. Edington, MD, discusses the utilization of tumor-infiltrating lymphocyte therapy in melanoma.

Dr. Fausel on the Evolution of Genomic Testing in Cancer Care

April 21st 2022

Christopher A. Fausel, PharmD, MHA, BCOP, discusses how genetic sequencing has played a growing role in cancer care.

Dr. Miller on the Current Treatment Landscape of Ovarian Cancer

April 19th 2022

Eirwen M. Miller, MD, discusses the current treatment landscape of ovarian cancer.

Dr. Moon on the Utilization of Relatlimab Plus Nivolumab in Metastatic Melanoma

April 19th 2022

Helen Heng-Shan Moon, MD, discusses the utilization of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

Dr. Barzi on Combination Regorafenib and Pembrolizumab in MSS CRC

April 19th 2022

Afsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.

Dr. Cohen on Potential With CAR T-Cell Therapy in Medullary Thyroid Cancer

April 19th 2022

Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).

GFRα4 May Represent a Unique Therapeutic Target in Medullary Thyroid Cancer

April 19th 2022

Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).

Dr. Edington on the Importance of Prevention Strategies in Melanoma

April 19th 2022

Howard D. Edington, MD, discusses the importance of prevention strategies in melanoma.

Dr. Cusnir on the Most Effective Uses of Chemotherapy Treatment in CRC

April 19th 2022

Mike Cusnir, MD, discusses the most effective uses of chemotherapy in colorectal cancer.